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INTRODUCTION
On March 11, 2020, the World Health Organization declared the 
coronavirus disease 2019 (COVID-19) outbreak a pandemic.1 
Many countries have tried to prevent the spread of COVID-19 
by avoiding physical contact and improving personal hygiene 
in public life. In medical institutions, further restrictions have 
also been implemented under limited resources, and most 
medical resources have been used to cope with the COVID-19 
pandemic. However, these efforts to prevent the spread of CO-
VID-19 caused significant changes in the diagnosis and treat-
ment processes of acute illness in the clinical field.2,3 Similarly, 
changes in the management of acute stroke care have also been 
reported in recent studies.4,5 However, these previous studies 
mainly focused on patients with acute ischemic stroke, not with 
acute hemorrhagic stroke. 
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Purpose: The coronavirus disease 2019 (COVID-19) pandemic disrupted the emergency medical care system worldwide. We an-
alyzed the changes in the management of intracerebral hemorrhage (ICH) and compared the pre-COVID-19 and COVID-19 eras.
Materials and Methods: From March to October of the COVID-19 era (2020), 83 consecutive patients with ICH were admitted to 
four comprehensive stroke centers. We retrospectively reviewed the data of patients and compared the treatment workflow metrics, 
treatment modalities, and clinical outcomes with the patients admitted during the same period of pre-COVID-19 era (2017–2019). 
Results: Three hundred thirty-eight patients (83 in COVID-19 era and 255 in pre-COVID-19 era) were included in this study. Symp-
tom onset/detection-to-door time [COVID-19; 56.0 min (34.0–106.0), pre-COVID-19; 40.0 min (27.0–98.0), p=0.016] and median 
door to-intensive treatment time differed between the two groups [COVID-19; 349.0 min (177.0–560.0), pre-COVID-19; 184.0 min 
(134.0–271.0), p<0.001]. Hematoma expansion was detected more significantly in the COVID-19 era (39.8% vs. 22.1%, p=0.002). At 
3-month follow-up, clinical outcomes of patients were worse in the COVID-19 era (Good modified Rankin Scale; 33.7% in COV-
ID-19, 46.7% in pre-COVID-19, p=0.039).  
Conclusion: During the COVID-19 era, delays in management of ICH was associated with hematoma expansion and worse out-
comes.
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Spontaneous intracerebral hemorrhage (ICH) is a disease 
that accounts for up to 24% of hemorrhagic strokes and can be 
fatal with a 1-month mortality rate of up to 40%.6-9 High blood 
pressure and hematoma expansion are associated with poor 
functional outcomes or death after ICH.10-12 Therefore, patients 
with ICH require acute intensive management regarding blood 
pressure and intracranial pressure to reduce the risk of a fatal 
outcome. As a result, management in the intensive care unit 
(ICU) is essential for patients with ICH.11-14 However, a signifi-
cant amount of medical resources is being consumed for the 
treatment of COVID-19, and little is known about the effect of 
this uneven distribution of resources on the acute management 
of ICH in the COVID-19 era. 
Globally, studies are being initiated in patients with acute 
hemorrhagic stroke.15,16 However, these studies have only shown 
the incidence of hemorrhagic stroke in patients with COVID-19, 
and information pertaining to the impact of COVID-19 on the 
treatment of hemorrhagic stroke is still lacking. 
Therefore, in the present study, we aimed to evaluate and 
compare the changes in the management of ICH between the 
pre-COVID-19 and COVID-19 eras. 
MATERIALS AND METHODS
Study design
Institutional Review Board of Catholic Kwandong University 
(IS20EIME0065), Yonsei University Severance Hospital (4-
2020-0577), Yonsei University Gangnam Severance Hospial (3-
2020-0364) and the National Health Insurance Service (NHIS) 
(NHIMC 2021-07-039) approved this study. Also, the need to 
obtain patient informed consent was waived because of the 
retrospective study design. The study was performed under 
the guidelines outlined by the Declaration of Helsinki, and the 
manuscript followed the STROBE checklist.
Patient population 
In this study, we defined the COVD-19 era as the period from 
March to October 2020, whereas the same period during the 
preceding three years i.e., March to October in 2017, 2018, and 
2019 is defined as the pre-COVID-19 era. Overall, during the 
pre-COVID-19 and COVID-19 eras, a total of 560 patients were 
admitted with ICH to four comprehensive stroke centers. 
Among them, the following patients were excluded: 1) patients 
aged <18 years; 2) patients who were transferred from another 
hospital under previous intensive treatment; 3) those whose 
diagnosis was delayed by >6 hours after symptom onset; and 
4) those with ICH due to aneurysm, arteriovenous malforma-
tion, or any vasculopathy. Finally, 338 patients (83 in the COV-
ID-19 era and 255 in the pre-COVID-19 era) were included in 
this study. 
All clinical and radiological data were obtained from elec-
tronic medical records and retrospectively reviewed and com-
pared between the COVID 19 and pre-COVID-19 era. 
COVID-19 prevention guidelines 
On February 20, 2020, the Korea Centers for Disease Control 
and Prevention issued guidelines on screening for COVID-19 
in emergency departments.17 According to the guidelines, a 
screening test of COVID-19 should be performed through a sep-
arate triage space for suspected patients with 1) pneumonia of 
unknown cause, 2) respiratory symptoms with a recent visit to 
a contaminated area within 14 days, or 3) respiratory symptoms 
with recent contact with a COVID-19 (+) patient within 14 days. 
Additionally, basic precautionary measures should be im-
plemented for all suspected patients, and contact and airborne 
precautions are to be applied depending on the situation (Fig. 
1). COVID-19 (+) or suspected patients should be isolated and 
treated in a negative pressure room within a triage space in the 
emergency department. Only authorized healthcare person-
nel can contact the COVID-19 (+) or suspected patient while 
wearing personal protective equipment. If the patient requires 
surgical or interventional treatment, intubation should be per-
formed only by authorized healthcare personnel in a negative-
pressure room or in an air-exchange room at least 12 times per 
Basic precaution
•  A mask should be put on the suspected patient while the patients is 
temporarily under quarantine in a separate place.
•  Suspected patients should maintain a distance of at least 1 meter 
from other patients.
•  All patients should be instructed to fold their tissues or arms to 
cover their nose and mouth when coughing or sneezing.
•  Hand hygiene should be performed after contact with respiratory 
secretions.
Contact precaution
•  Contact caution prevents both direct and indirect spread of the 
disease that occurs through contact with contaminated surfaces or 
materials.
•  When entering a hospital room, physicians should wear personal 
protective equipment (mask, eye protection, gloves, and gown) and 
remove the personal protective equipment before leaving the room.
•  If possible, use disposable equipment (e.g., stethoscope, cuff, 
thermometer, etc.).
•  When items (devices) are shared among patients, each item should 
be cleaned and disinfected before use.
•  Patients’ movement or transportataion is restricted and allowed 
only when absolutely necessary.
Airborne precaution
•  In the event of possible aerosol generation (open air suction, 
tracheal intubation, bronchoscopy, cardiopulmonary resuscitation, 
etc.), medical practitioners should wear gloves, long-sleeved gowns, 
eye protection, and fit-tested respiratory protection (N95 mask) as 
personal protective equipment. 
•  If possible, patients should be managed in a room with air exchange 
12 times an hour.
•  Only essential personnel should be allowed in the negative-pressure 
containment room.
•  After starting mechanical ventilation, the patient should be 





























Fig. 1. Korea Centers for Disease Control and Prevention guidelines for 
COVID-19 in medical institutions. COVID-19, coronavirus disease 2019.
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hour. As the number of healthcare personnel participating in 
the surgery or intervention is limited, all of them should wear 
personal protective equipment (full-body protective clothing, 
N95 masks, gloves, hats, goggles, or face shields); powered air-
purifying respirators may be used, if possible. Then, the COV-
ID-19 (+) or suspected patient should be treated in a specialized 
ward or ICU for COVID-19. After the confirmation of COVID-19 
(-), all processes should be routinely conducted in the usual 
manner. The four comprehensive stroke centers participating in 
this study followed all of the aforementioned guidelines. 
Image study analysis
Based on the protocol of the institution, follow-up computed 
tomography (CT) images were obtained after admission to 
evaluate hematoma expansion. Most patients had a follow-up 
CT scan performed on the following day, 12–24 hours after 
symptom onset/detection, unless their neurologic status wors-
ened or they were suspected to have experienced a change in 
their intracranial pressure. ICH volume was defined using the 
ABC/2 formula, and assessed at the time of each CT scan. He-
matoma expansion was determined as an increase in the initial 
volume by >33% or an increase of hematoma volume by >6 mL 
in the follow-up CT scan, as reported in previous studies.18-21 
The image acquisition, measurement, and analysis were con-
ducted by three independent investigators (H.J.H, Y.H.L, and 
S.Y.K). In case of disagreement, another neurosurgeon (K.Y.P) 
reviewed the data, and four investigators decided on the final 
results with consensus. 
Outcome measurements
The following workflow metrics (measured in minutes) of each 
patient were evaluated: 1) symptom onset/detection-to-door 
time; 2) door-to-imaging time; 3) door-to-intensive treatment 
time; and 4) overall symptom onset/detection-to-intensive 
treatment time. Intensive treatment was defined as the best 
medical treatment for managing blood pressure and intracra-
nial pressure, correction of coagulopathy, or reversal of antico-
agulants in the neuro-critical care unit. Surgical treatment was 
also divided into catheter surgery and open surgery. At the 90-
day follow-up, functional outcome was assessed by experi-
enced neurosurgeons or rehabilitation medicine physicians us-
ing the modified Rankin Scale (mRS). An unfavorable outcome 
was defined as mRS score of 3 or more. All variables were com-
pared between the COVID-19 and pre-COVID-19 groups. 
Statistical analyses
For comparison between the two groups, univariate analysis 
was performed using chi-squared test, Fisher’s exact test, Mann–
Whitney U test, and standard t-tests. Multivariable analysis was 
performed on variables with a p<0.10 on univariate analysis. 
Binary logistic regression analysis was used to perform multi-
variable analysis for hematoma expansion and 90-day func-
tional outcome. Significance was defined as p<0.05. Statistical 
analyses were performed using IBM SPSS Statistics version 
25.0 for Windows (IBM Corp., Armonk, NY, USA).
RESULTS
During the COVID-19 era, 83 patients (average age of 63.4 years) 
were treated for ICH in four comprehensive stroke centers. In 
the same period during the pre-COVID-19 era, 255 patients (85 
patients/year, average age of 60.7 years) were treated for ICH in 
the same centers. There were no significant differences in base-
line characteristics, medical history, or initial GCS between the 
two groups (Table 1). 
Regarding workflow metrics, symptom onset/detection-to-
door time was significantly different between the two groups 
[COVID-19; 56.0 min (34.0–106.0), pre-COVID-19; 40.0 min 
(27.0–98.0), p=0.016]. Door-to-imaging time did not signifi-
cantly differ between the two groups, but showed a tendency 
to delay in the COVID-19 group [COVID-19; 24.0 min (15.0–
38.0), pre-COVID-19; 20.0 min (13.0–32.0), p=0.082]. Door-to-
intensive treatment time [COVID-19; 349.0 min (177.0–560.0), 
pre-COVID-19; 184.0 min (134.0–271.0), p<0.001] showed a 
significant delay during the COVID-19 era. Finally, the overall 
symptom onset/detection-to-intensive treatment time was 
significantly delayed in the COVID-19 group [COVID-19; 430.0 
min (248.0–640.0), pre-COVID-19; 255.0 min (189.0–375.0), p< 
0.001] (Table 2 and Fig 2).
Table 3 shows a comparison of the characteristics of the he-
matoma expansion (+) and (-) groups. Previous cerebrovascu-
lar accident (CVA) history (p<0.001), antithrombotic usage 
(p<0.001), initial GCS (p=0.011), and delayed door-to-inten-
sive treatment time (p=0.046) were risk factors related to hema-
toma expansion. In the multivariable logistic regression analy-
sis, previous cerebrovascular accident (CVA) history [odds ratio 
(OR): 2.818, 95% confidence interval (CI): 1.438–5.522]; low 
initial GCS (OR: 1.108, 95% CI: 1.037–1.184); and delayed door-
to-intensive treatment time (OR: 0.998, 95% CI: 0.997–1.000) 







Age, yr 63.4 (14.4) 60.7 (16.4) 0.185
Sex, male 43 (51.8) 148 (58.0) 0.320
Medical history
Hypertension 48 (57.8) 149 (58.4) 0.923
Current smokers 32 (38.6) 90 (35.3) 0.591
Antithrombotic usage 27 (32.5) 66 (25.9) 0.239
Previous CVA 20 (24.1) 54 (21.2) 0.576
Initial GCS 11.6 (4.00) 10.9 (4.30) 0.175
COVID-19, coronavirus disease 2019; SD, standard deviation; CVA, cerebro-
vascular accident; GCS, Glasgow Coma Scale.
Data are presented as mean (SD) or n (%).
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were significant independent risk factors for hematoma expan-
sion (Table 4).
At the 90-day follow-up visit (available in all patients), pa-
tients in the COVID-19 group had a worse functional outcome 
compared to those in the pre-COVID-19 group (Table 5 and Fig. 
3). In the analysis restricted to patients who were independent, 
55 patients (66.3%) in the COVID-19 group and 136 patients 
(53.3%) in the pre-COVID-19 group had an unfavorable mRS 
score (≥3) (p=0.039). In the multivariable logistic regression 
analysis, COVID-19 era (OR: 3.122, 95% CI: 1.571–6.203); low 
initial GCS (OR: 0.663, 95% CI: 0.593–0.741); hematoma expan-
sion (OR: 2.003, 95% CI: 1.004–3.997); medical intensive care 
(OR: 4.057, 95% CI: 1.984–8.298); and older age (OR: 1.038, 
95% CI: 1.017–1.060) were independent predictors of an unfa-
vorable functional outcome at 90 days (Table 5).
DISCUSSION
During the last year of the COVID-19 pandemic, 2020, govern-
ments and medical institutions have done their best to pre-
Fig. 2. Comparison of workflow metrics in the management of ICH be-
tween COVID-19 and pre-COVID-19 eras. The symptom onset/detec-
tion-to-door time was significantly different between the two groups 
[COVID-19; 56.0 min (34.0–106.0), pre-COVID-19; 40.0 min (27.0–98.0), 
p=0.016]. Also, door-to-intensive treatment time [COVID-19; 349.0 min 
(177.0–560.0), pre-COVID-19; 184.0 min (134.0–271.0), p<0.001] showed a 
significant delay during the COVID-19 era. *p-value considered statisti-
cally significant. COVID-19, coronavirus disease 2019; ICH, intracerebral 
hemorrhage.

































Hematoma expansion† 33 (39.8) 47 (22.1) 0.002*
Treatment modality 0.180
Medical intensive care 56 (67.5) 151 (59.2)
Surgical treatment 27 (32.5) 104 (40.8)
Surgical treatment 0.170
Catheter surgery 18 (66.7) 54 (51.9)
Open surgery 9 (33.3) 50 (48.1)
 90-day functional outcome 0.039*
Unfavorable (mRS ≥3) 55 (66.3) 136 (53.3)
COVID-19, coronavirus disease 2019; IQR, iterquartile range; mRS, modified 
Rankin Scale.
 Workflow metrics measured in minutes. Data are presented as median (IQR) 
or n (%).



































Age, yr 63.1 (14.4) 61.5 (16.3) 0.420
Sex, male 50 (62.5) 118 (54.6) 0.225
Medical history
Hypertension 50 (62.5) 125 (57.9) 0.472
Current smokers 36 (45.0) 77 (35.6) 0.141
Antithrombotic usage 37 (46.3) 48 (22.2) <0.001*
Previous CVA 34 (42.5) 37 (17.1) <0.001*
Initial GCS 10.0 (4.23) 11.4 (4.22) 0.011*
Symptom onset/detection-to- 




















90-day functional outcome 0.003*
Unfavorable (mRS ≥3) 57 (71.3) 113 (52.3)
SD, standard deviation; CVA, cerebrovascular accident; GCS, Glasgow Coma 
scale; IQR, interquartile range; mRS, modified Rankin Scale.
Workflow metrics measured in minutes. Data are presented as mean (SD) or 
n (%).
*Statistically significant.
Table 4. Multivariable Analysis of Hematoma Expansion
Multivariable analysis
OR 95% CI
Antithrombotic usage 1.780 0.942–3.363
Previous CVA history 2.818 1.438–5.522
Initial GCS 1.108 1.037–1.184
Symptom onset/detection-to-door time 1.001 0.997–1.004
Door-to-intensive treatment time 0.998 0.997–1.000
OR, odds ratio; CI, confidence interval; CVA, cerebrovascular accident; GCS, 
Glasgow Coma Scale.
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Fig. 3. Comparison of the 90-day functional outcomes between COVID-19 
and pre-COVID-19 eras. COVID-19, coronavirus disease 2019.
vent the spread of COVID-19 around the globe. However, in 
conjunction with these efforts, the pandemic might affect the 
management of patients with acute illness due to limited medi-
cal resources, the overload in public healthcare, and inordinate 
public fear of COVID-19. Consistent with these limitations, Tam, 
et al.3 detected a significant time delay in the management of 
acute ST-segment–elevation myocardial infarction, and Schrag 
et al.2 predicted that rapid changes in oncology practice would 
occur due to the prevention of COVID-19 spread, remote man-
agement, and consecutive treatment omission or delay. 
Despite the COVID-19 outbreak, many stroke experts have 
tried to maintain acute stroke care and proposed modified al-
gorithms in the current situations.22,23 Smith, et al.23 designed an 
algorithm for acute stroke care according to the airway main-
tenance requirements, resources availability, and stability for 
transport. Nguyen, et al.22 suggested that thrombectomy should 
be performed with the minimum number of medical person-
nel under protection, using communication equipment such 
as telecommunication and environmental management. Last-
ly, a recent study has shown that there was no delay in acute 
stroke management, including in-hospital workflow metrics.24 
Unfortunately, such efforts were mainly limited to acute isch-
emic stroke management, as only few hospitals have protocols 
specific to the management of ICH comparing with acute isch-
emic stroke.25 
Several studies also reported that the COVID-19 pandemic 
decreased the number of hospital admissions and reperfu-
sion therapy. In a study by Rudilosso, et al.4 in March 2020, the 
number of stroke codes in Catalonia declined by 23% compared 
to that of March 2019 (p=0.009). In another study by Zhao et al.,26 
a significant decrease in reperfusion therapy in China was re-
ported (p<0.0001), and it was suggested that the potential rea-
son for the decreased number of stroke patients was a “fear of 
contracting COVID-19 in hospital.”27 On the other hand, in the 
present study, the number of hospital admissions during the 
COVID-19 era (2020) was not different compared to the same 
period during the pre-COVID-19 era (2017–2019). It remains 
uncertain as to why the number of patients with ICH did not 
decrease during the COVID-19 era, unlike of those with acute 
ischemic stroke or coronary disease. In our theory, it is because 
patients with ICH present with more severe neurological sta-
tus, and many patients or their legal representatives might 
have a “fear of fatality due to hemorrhagic stroke” rather than 
a “fear of contracting COVID-19 in hospital.” This result was 
also supported by a study by Diegoli, et al.,28 in which the num-
ber of admissions for ischemic stroke was significantly de-
creased in Joinville, but that for hemorrhagic stroke, including 
intraparenchymal and subarachnoid hemorrhage, was not dif-
ferent between the pre-COVID-19 and COVID-19 eras. 
In the present study, the ICH patient group of the COVID-19 
era showed a significant time delay in both symptom onset-
to-intensive treatment time and door-to-intensive care time. 
In subgroup analysis, the door-to-intensive treatment time was 
markedly increased in patients whose history was unclear or 
those who were suspected of being infected with severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), compared 
to the patients not suspected to be infected (427.3 minutes and 
207.8 minutes, respectively). In the emergency room, the wait-
ing time for the SARS-CoV-2 test result or for available ICU 
beds among those categorized as possible COVID-19 patients 
might be increased. Generally, if the operation of an emergency 
department focuses on the prevention of SARS-CoV-2 transmis-
sion, this affects the treatment process of many acute illnesses, 
including the workflow of ICH management. Since there was 
no secured transport pathway from the emergency room to the 
operating room and from the operating room to the ICU, delays 
in patient transfer were unavoidable. The changes introduced 
in the COVID-19 era led to delays, which resulted in hemato-
ma expansion.
Hematoma expansion, one of the major concerns of acute 
ICH management, occurred more frequently during the COV-
ID-19 era, which led to a poorer clinical outcome than in the 
pre-COVID-19 era. In the literature, hematoma expansion is 
known to occur in up to 30% of patients, and several studies 
have suggested that intensive treatment, including blood 
pressure control, reversal of coagulopathy, and surgical treat-
Pre-COVID-19
COVID-19
0                 20                 40                 60                 80               100
15.66%
20.78% 10.59% 15.29% 6.67% 19.22%
p-value=0.039
12.16% 15.29%









Table 5. Univariate and Multivariable Regression Analyses of Unfavor-
able Functional Outcomes at 90 Days
Univariate analysis Multivariable analysis
OR 95% CI OR 95% CI
COVID-19 era 1.719 1.025–2.883 3.122 1.571–6.203
GCS 0.635 0.573–0.703 0.663 0.593–0.741
Hematoma expansion (+) 3.641 2.142–6.191 2.003 1.004–3.997
Medical intensive care 8.811   5.072–15.305 4.057 1.984–8.298
Age 1.018 1.004–1.032 1.038 1.017–1.060
OR, odds ratio; CI, confidence interval; COVID-19, coronavirus disease 2019; 
GCS, Glasgow Coma Scale.
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ment, can increase the chance of a better clinical outcome in 
patients with ICH.29-32 However, in the COVID-19 era, the choice 
between open craniotomy and catheter surgery was also a ma-
jor concern. Clinician’s protection, ventilation and disinfec-
tion of operative rooms, and secured transport pathways were 
also considered in surgical decision-making. In this study, we 
had to decide which surgery to perform in two ICH patients who 
were suspected to have COVID-19. Open craniotomy could not 
be performed, as the surgeons could not access the microscope 
while wearing personal protective equipment, and both patients 
experienced unfavorable 90-day functional outcomes.
In terms of clinical outcome, the functional outcome at 90 
days of ICH patients was worse in the COVID-19 era than in the 
pre-COVID-19 era. In the multivariable analysis, an unfavorable 
90-day functional outcome was associated with low GCS, medi-
cal intensive care only, and advanced age. The association be-
tween advanced age and poor functional outcome at 90 days 
might be due to some older patients with large hematomas re-
fusing surgical treatment. More importantly, hematoma expan-
sion and the COVID-19 era were associated with unfavorable 
functional outcomes at 90 days, and delay of door-to-intensive 
care time was a significant risk factor for hematoma expansion. 
In the COVID-19 era, delay in the emergency room and inter-
ference of ICH workflow might lead to hematoma expansion; 
as a result, the overall changes might be associated with unfa-
vorable clinical outcomes. 
To our knowledge, the present study is the first regarding 
delays in the management of patients with ICH in the COV-
ID-19 era. However, our study had several limitations. First, due 
to the limitations inherent in the retrospective design with 
short-term follow-up, a selection bias was inevitable regarding 
the demographics and percentages observed. Second, the pop-
ulation of this study was limited to the specific area of South 
Korea. Therefore, our results cannot be generalized and direct-
ly applied to other areas or countries around the world. Also, 
the ICH and hematoma expansion volume could not be mea-
sured, and accurate records of the CT follow-up time could not 
be obtained. Nevertheless, to the best of our knowledge, this 
study is the first and the largest study on ICH management in 
the COVID-19 pandemic, and could be helpful in evaluating 
stroke management in the COVID-19 era in future studies.
These results illustrate the adverse effect of non-standard-
ized ICH management in the COVID-19 era on functional 
outcomes as a consequence of changes in the workflow metrics 
and increased hematoma expansion. During the COVID-19 
era, ICH management was delayed, and hematoma expansion 
occurred more frequently. Furthermore, clinical outcomes 
were significantly different from those of the pre-COVID-19 era. 
Considering the results of this study, the treatment process for 
ICH patients in the COVID-19 era should be reviewed, and de-
veloping a special intensive care protocol for ICH patients 
should be considered. 
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